A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence, Swedish ...

Fear of discomfort and unnecessary treatment often deters patients from prostate cancer screening, despite the benefits of early detection. Prostate cancer can be asymptomatic, making early detection ...

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

Drs. Pallabi Mustafi and Ruben Raychaudhuri at Fred Hutch Cancer Center recently received Young Investigator Awards from the ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Prostate cancer kills around 3,900 Australians a year.

Most men with low-grade prostate cancer have an excellent prognosis, with a five-year survival rate of more than 99%. But ...